S308 I?2. Psychotic disorders and antipsychotics 2252 patieuts were enrolled from 8 countries withiu the CEE region: the Czech Republic (22%), Huugary (9%), Lithuania (5%), Poland (28%), Romania (6%), Russia (7%), Slovakia (13%), aud Sloveuia (10%). Patients prescribed olauzapiue showed signifi- tautly greater improvements in overall, negative aud depressive symptom severity followiug 3 aud 6 mouths treatment compared to patients taking risperidoue or ‘other autipsychotics’ (p~O.001). Olauzapiue-treated patients also improved significantly more with respect to positive aud cognitive symptoms after both 3 aud 6 mouths compared to patients taking ‘other autipsychotics’ (piO.0001). Fewer patients in the olauzapiue group (4%) de- veloped EPS during the 6-mouth study period compared with the risperidoue (11%) or ‘other autipsychotic’ (12%) treatment groups. Of those patients in the olauzapiue group that had EPS at baseline, 75% recovered from these symptoms compared with 60% aud 52% in the risperidoue aud ‘other autipsychotic’ groups, respectively. Similarly, at 6 mouths, the proportiou of patients with remission of TD was higher for olauzapiue (68%), compared with risperidoue (39%) or ‘other autipsychotic’ (34%) treatment. The uew iucideuce of sexual dysfuuctiouiimpoteuce was lower for olauzapiue-treated patients (6%) at 6 mouths compared to risperidoue (15%) aud ‘other autipsychotics’ (13%), respectively. A greater proportiou of olauzapiue-treated patients exhibited a remission of symptoms associated with sexual dysfuuctiou after 6 mouths compared to the other treatment cohorts (45%, 33% aud 25% for olauzapiue, risperidoue aud ‘other autipsychotics’ , re- spectively). Patients ou olauzapiue gamed significantly (pi 0.001) more weight (2.115.2 kg) thau those taking ‘other autipsychotics’ (1.014.2 kg) or risperidoue (1.114.0 kg). However, the meau chauge in BMI was uot significant betweeu the treatment groups at the level of 0.001. Social fuuctiouiug was improved at 6 mouths for olauzapiue-treated patients compared to ‘other autipsychotics’ Conclusions: After 6 mouths, patients treated with olauzapiue in the CEE region, as used in clinical practice, showed greater improvements in terms of effectiveness of treatment, safety aud fuuctioual status compared to risperidoue or ‘other autipsychotics’ treated patients. Evaluatiou will coutiuue prospectively throughout the remainder of this study. m P2 067 An analysis of tardive dyskinesia in intercontinental outpatients with schizophrenia C. Osvaldo’, M. Dosseubach2, J.M. Tamayo3, D. Soria4, C. Na5, S. Siugh’, K.-H. Wu7. ‘First Hospital Panamericano, Dept. of Psychiatry, Cidra, Puerto Rico; 2Eli Lilly, Regional Operations, Ges.m.D.H, Vienna, Austria; 3Eli Lilly & Co., Puerto Rico; 41MSS Saltillo, Dept Psiquiatria, Mexico; ‘Chung-Ang University Medical School, Seoul, Republic of Korea; 6Hospital Kota BHaru, Kel, Dept. of Psychiatry, Kelantan, Malaysia; 7McKay Memorial Hospital, Taipei, Taiwan S. Kasper’ , A.J. Lowry2, A. Hodge2, I. Bitter3, M. Dosseubach3. ’ University of Vienna, Dept. of Psychiatry, Vienna, Austria; 2Eli Lilly Australia, PlY Limited, Clinical Outcomes and Research Institute, NSW, Australia; 3Eli Lilly, Regional Operations, Ges.m.D.H, Vienna, Austria Objective: To determine the point prevalence of tardive dyski- uesia (TD) in a regioually diverse populatiou of outpatients with schizophrenia in order to facilitate identification aud evaluatiou of poteutial risk factors. Background: IC-SOHO (Iutercoutiueutal Schizophrenia Outpa- tieuts Health Outcomes) is a 3-year global, prospective, obser- vatioual study examining health outcomes for outpatients with schizophrenia uudergoiug treatment with autipsychotics. In this preseutatiou, we describe the effect of autipsychotic treatments ou sexual fuuctiouiug of patients with schizophrenia 6 mouths after eiirolineiit. Objective: To examine the side effects associated with sexual fuuctiouiug in patients with schizophrenia followiug 6 mouths of autipsychotic therapy. Methods: This analysis was derived from the Iutercoutineutal Method: Subjects > 18 years of age, uudergoiug treatment for Schizophrenia Outpatients Health Outcomes study (IC-SOHO). schizophrenia in au outpatient setting aud either chaugiug or iui- Patients (11=7648) either iuitiatiug or chaugiug autipsychotic med- tiatiug autipsychotic treatment, were enrolled at the discretion of icatiou therapy were enrolled to take part in this prospective, their psychiatrist. Two treatment groups were established for post 3-year observational study of health outcomes. Approximately hoc analysis: prolactiu-elevating (consisting of typical autipsy- half of the patient populatiou were prescribed olauzapiue, with the chotics, risperidoue aud amisulpride) aud non-prolactiu-elevatiug remainder prescribed auy other additioual autipsychotic available. (all atypical autipsychotics except risperidoue aud amisulpride) Twenty-seven countries from Latin America, Asia, Africa aud autipsychotic treatments. Further analysis comparing sexual dys- the Middle East, aud Central aud Easteru Europe were iuvolved. fuuctiou in patients prescribed olauzapiue, risperidoue or haloperi- The relationships betweeu age, gender, duration of schizophrenia do1 was conducted. Physicians recorded the presence of symptoms diagnosis, autipsychotic exposure, region aud prevalence of TD were examined using logistic regression analysis. Patients will be routinely assessed throughout the study to determine the remission, persistence aud development of TD over the course of therapy. Results: The overall prevalence of TD in this iutercoutineutal populatiou was 8.3%. Irrespective of gender, both time post- diagnosis of schizophrenia (piO.0001) (see Table 1) aud age (piO.0001) were positively associated with TD prevalence. In addition, duration of diagnosis aud age were found to be additive. Table I. Effect of duration of schizophrenia diagnosis on TD prevalence. Duration of diagno- O-1 2-5 6-10 II-15 16-20 >21 sis, years (95% CI) % Females with TD 5. I 6.3 6.5 9.0 9.4 15.3 (3.6-7.0) (4.4-8.6) (459.1) (6.4-12.2) (6.2-13.6) (12.1-18.8) % Males with TD 4.6 6.2 7.8 8.2 10.8 20.5 (3.462) (4.7-8.1) (5.8-10.1) (5.7-11.2) (7.7-14.8) (17.S24.4) After adjusting for age aud duration of schizophrenia diagnosis, males (p=O.Ol) were more at risk for TD thau their female counterparts. Followiug similar adjustment, patients with prior autipsychotic exposure were also significantly more at risk of developiug TD (p=O.O02). Regional variatiou in prevalence was explaiued by uuderlyiug demographic differences. Conclusions: Duration of schizophrenia diagnosis aud age were prognostic indicators of TD in this outpatient population, aud, in addition, prior exposure to autipsychotics aud male gender further iucreased risk. m P2 068 Antipsychotic treatment for schizophrenia: Effects on sexual function